Cargando…
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Autores principales: | Ye, Liping, Lin, Chuyong, Wang, Xi, Li, Qiji, Li, Yue, Wang, Meng, Zhao, Zekun, Wu, Xianqiu, Shi, Dongni, Xiao, Yunyun, Ren, Liangliang, Jian, Yunting, Yang, Meisongzhu, Ou, Ruizhang, Deng, Guangzheng, Ouyang, Ying, Chen, Xiangfu, Li, Jun, Song, Libing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899907/ https://www.ncbi.nlm.nih.gov/pubmed/35253379 http://dx.doi.org/10.15252/emmm.202115618 |
Ejemplares similares
-
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2019) -
GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer
por: Ouyang, Fei, et al.
Publicado: (2021) -
BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate
por: Huang, Xinjian, et al.
Publicado: (2023) -
Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer
por: Wang, Meng, et al.
Publicado: (2021) -
Overexpression of HES6 has prognostic value and promotes metastasis via the Wnt/β-catenin signaling pathway in colorectal cancer
por: Xu, Yuandong, et al.
Publicado: (2022)